Q5128 is the HCPCS code for: Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg. In 2024, 470 providers billed Q5128 937,303 times, with an estimated $169.3M paid by Medicare.
Q5128 is a Part B drug code: Medicare pays an ASP-based rate of $82.53 per 0.1 mg (2026 Q3 ASP drug pricing file). Total payment per patient depends on the dose billed.
A billed "service" on this code is one 0.1 mg unit, not one patient visit — that's why the service counts below run high.
What Medicare actually paid per service in 2024, on average: $180.63 (observed payment across all settings and modifiers — not a fee-schedule rate).
The top 5 billers nationally, ranked by 2024 Medicare service volume.
| # | Provider | Specialty | Location | Services | Est. Medicare paid |
|---|---|---|---|---|---|
| 1 | Omesh Gupta, MD | Ophthalmology | Plymouth Meeting, PA | 18,534 | $3.3M |
| 2 | Richard Kaiser, MD | Ophthalmology | Plymouth Meeting, PA | 18,370 | $3.3M |
| 3 | Mitchell Fineman, MD | Ophthalmology | Plymouth Meeting, PA | 13,985 | $2.5M |
| 4 | Marc Spirn, MD | Ophthalmology | Plymouth Meeting, PA | 13,036 | $2.4M |
| 5 | James Vander, MD | Ophthalmology | Plymouth Meeting, PA | 12,932 | $2.3M |
Prospect 811 answers "what is this code, what does it pay, and who bills it?" for every billable code — then filters the answer to your exact territory, with phone numbers. $79/month, no contract, 14-day refund.
Start prospecting →